Novartis Ends BioArctic Brain Delivery Deal After 14 Months

Novartis has ended a brain drug delivery partnership with Swedish biotech BioArctic, about 14 months after the two companies signed it. BioArctic disclosed the decision on November 2, 2026. It said Novartis chose to stop the program, and that the move had nothing to do with BioArctic's technology.

What happened

BioArctic said Novartis Pharma AG notified it that it would terminate the option, collaboration and licence agreement the pair entered into in August 2025.

The deal aimed to pair BioArctic's BrainTransporter technology with an undisclosed Novartis antibody. Under the plan, BioArctic would build a drug candidate. Novartis would then review the data and decide whether to license it and lead global development and sales, according to Pharmaceutical Executive.

• Upfront: $30 million, which BioArctic keeps in full.
• Milestones: up to $772 million in possible payments, as reported by Pharmaceutical Executive.
• Royalties: tiered, in the mid single digits, on global sales of any approved product, per the same report.

BioArctic said it will book the part of the upfront payment it has not yet recognized as revenue in 2026.

Why it matters

BrainTransporter uses the transferrin receptor to help drugs cross the blood-brain barrier. BioArctic says the approach can improve how a drug spreads through the brain, and may help with safety and dosing.

BioArctic stressed that the decision came from Novartis ending the program, not from a problem with the platform.

BioArctic said it has signed five collaboration agreements using BrainTransporter to date. Pharmaceutical Executive noted that one is a global licence with Bristol Myers Squibb, signed in December 2024 for $100 million upfront and up to $1.25 billion in milestones. Eisai signed a research evaluation agreement in April 2024. BioArctic is best known for inventing the Alzheimer's drug Leqembi, which it developed with Eisai.

What it means for people in the industry

Neither source reports job changes linked to the decision. In a separate interview in August about the state of pharma and biotech dealmaking, Norstella's Dan Chancellor told Pharmaceutical Executive that companies are dropping weak assets before they get expensive.

For BioArctic, the next signals to watch are progress in its other BrainTransporter partnerships and its own brain-targeted projects in Parkinson's disease, ALS and Alzheimer's disease.

See open pharma jobs in the US and Canada

Sources

• BioArctic collaborator Novartis terminates agreement, BioArctic via PR Newswire
• Novartis Exits BrainTransporter Deal with BioArctic 14 Months After Signing, Pharmaceutical Executive